selective serotonin reuptake inhibitor

Phase 3Small molecule

selective serotonin reuptake inhibitor is one of 52 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderRecruiting

Major Depressive EpisodeActive, not recruiting

Major Depressive DisorderPhase 3

Recruiting

Major Depressive EpisodePreclinical

Active, not recruiting

Competition

Competitive Landscape

120 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Ketalar

Boehringer Ingelheim

Phase 3

3 3

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 4

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 5

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 6

Psilocybin

COMPASS Pathways

Phase 3

11 7

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 8

Aticaprant

Johnson & Johnson

Phase 3

4 9

CYB003

CCybin IRL Limited

Phase 3

3 10

Azetukalner

XXenon Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Major Depressive Disorder

NCT07703722

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03321526·107 enrolled

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial

Recruiting·KKhyber Medical University Peshawar·Phase 3·NCT07703722·60 enrolled

Treatment1 trial

Predicting Treatment Response in Patients With OCD

Completed·UUniversity of Sao Paulo·Phase 4·NCT03993535·250 enrolled

Effectiveness1 trial

Sequenced Treatment Effectiveness for Posttraumatic Stress

Completed·UUniversity of Washington·Phase 4·NCT04597190·700 enrolled

Adolescent1 trial

An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression

Completed·UUniversity of Minnesota·Phase 2·NCT03222570·90 enrolled

Major Depressive Episode1 trial

Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis

Completed·PPamlab, Inc.··NCT01001559·242 enrolled

2 more indications

Bipolar Depression1 trial

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

Completed·TThe Cleveland Clinic·Phase 4·NCT01811147·192 enrolled

Nerve Block1 trial

Success of Inferior Alveolar Nerve Block in Women Taking Selective Serotonin Reuptake Inhibitors

Completed·IIsfahan University of Medical Sciences··NCT02884596·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for selective serotonin reuptake inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — selective serotonin reuptake inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for selective serotonin reuptake inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

selective serotonin reuptake inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Major Depressive Disorder2 trials

Treatment1 trial

Effectiveness1 trial

Adolescent1 trial

Major Depressive Episode1 trial

Bipolar Depression1 trial

Nerve Block1 trial

References

Drug Info

Quick Facts

Related News